English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
When Ayahuasca Tells You to Stay: Reading Messages From the Medicine
Picture this. You drink the brew expecting clarity about your next move — a new city, a new partner, a new version of yourself — and instead the medicine puts a hand on your chest and says, gently but firmly, stay. Not just once. Three ceremonies in a row. Maybe five. Maybe across two different retreats with two different facilitators on two different continents. This happens more often than people talk about. Ayahuasca rarely hands out the answers we ordered. Anyone who has spent real time around plant medicine has either lived this or watched a friend live it — the message that refuses to budge, even when every part of the rational mind is begging for permission to leave a relationship, a job, a city, a story about who they are. So what do you do when the vine keeps telling you not to move on from something — or someone — you were sure you needed to leave behind? There's a common assumption among first-timers that ayahuasca is a kind of cosmic search engine. Ask a clear question, get a clear answer, ideally one that confirms what you already suspected. The reality is messier. People who've sat in many ceremonies will tell you the medicine often answers a different question than the one you asked — usually a more honest one. If you went in asking should I leave my marriage? and the brew kept showing you your own avoidance patterns, your unfinished grief about your father, the part of you that runs the second anything gets uncomfortable — that's not the medicine dodging the question. That's the medicine answering the question underneath the question. The one you didn't have the courage to ask out loud. This is part of why experienced facilitators talk less about ayahuasca guiding you and more about ayahuasca revealing you. The plant doesn't write the script. It turns the lights on in rooms you've been pretending not to notice. Here's the question that haunts most people in this situation: how do I know the difference between genuine plant-medicine guidance and my own fear dressed up in shamanic clothing? It's a fair question. Ayahuasca journeys are vivid, emotional, and easy to interpret through whatever lens you brought in with you. A few honest signals that point toward real guidance rather than projection: Fear, by contrast, is loud and circular. It uses your own voice. It tells you stories about catastrophe, abandonment, humiliation. Medicine messages, when they're real, tend to feel oddly impersonal — like someone reading you the weather forecast rather than shouting at you from across a room. That said, nobody — not your facilitator, not a shaman with forty years of experience, not the loudest voice in your integration circle — can tell you with total certainty which is which. You have to learn to listen, and that takes time. When the medicine tells someone not to move on from a person, a place, or a chapter of their life, it almost never means what the literal English words suggest. Ayahuasca speaks in image, feeling, and metaphor. "Don't move on" rarely translates to stay exactly as you are, doing exactly what you've been doing. From conversations across many ceremonies, here are some of the things it has been understood to mean: None of this is a command to stay in something genuinely harmful. The medicine isn't asking you to tolerate abuse, neglect, or addiction-driving environments. If anything, in those cases, ayahuasca tends to be unmistakable about getting out. "Don't move on" usually shows up in the murkier territory — the relationship that isn't bad, just unresolved; the city you keep almost leaving; the version of yourself you keep almost letting die. The hardest part of plant-medicine work isn't the ceremony itself. It's the months afterward, when you're back in your kitchen at 7am trying to figure out what to actually do with what you heard. Integration is where the real work lives, and it's where most people quietly lose the thread. If the medicine has told you not to move on from something, and that message has stayed consistent across sittings, a few practices tend to help: It's also worth sitting with the possibility that the message will change. Ayahuasca isn't issuing a life sentence. It's offering a current reading. A year from now, after you've actually done the work the medicine asked of you, the instruction may shift. Many people who were told to stay eventually receive a clear sense that they're free to go — and by then, leaving means something completely different than it would have at the start. Plant medicine is powerful but it isn't infallible, and neither is your interpretation of it. Trust the message most when it has these qualities: consistency across ceremonies, calm rather than urgency, specificity about your own behavior rather than someone else's, and an uncomfortable resonance with something you already half-knew. Be more skeptical when the message arrives once in a particularly intense moment, contradicts everything you've previously received, asks you to do something that would harm you or others, or comes loaded with grandiose language about destiny and soulmates. The medicine tends toward humility, not melodrama. And remember: a good facilitator, a thoughtful integration therapist, and your own body's slow wisdom are all part of how you make sense of this. Ayahuasca isn't meant to replace your judgment. It's meant to expand the field of what you can perceive, so your judgment has more to work with. For readers who want to take this further and find a setting where this kind of work is held carefully, a range of curated ayahuasca retreats can be browsed on our marketplace here. The decision about whether and where to sit is yours — but the medicine, as anyone who has worked with it knows, has a way of telling you when it's time.
Why Juneteenth Matters Beyond the Black Community: A Reflection
On June 19, 1865, Union troops rode into Galveston, Texas and announced that the people enslaved there were free. The Emancipation Proclamation had been signed two and a half years earlier. Word, somehow, hadn't traveled. That gap between a legal truth and a lived one is the heart of Juneteenth — and it's the reason the day still matters, far beyond the community that birthed the celebration. For more than a century and a half, Black families gathered every June 19 to mark the moment freedom finally arrived. In 2021, after decades of grassroots advocacy, Congress made it a federal holiday. The vote moved through both chambers faster than almost anyone expected — a striking contrast to the thirty-plus years it took to establish the Martin Luther King Jr. holiday. Things have shifted. Other things haven't. If you've spent any real time with contemplative practice — Buddhist, yogic, plant-medicine, anything serious — you've bumped into the same idea over and over. The whole project is liberation. Freedom from craving, freedom from fear, freedom from the patterns that keep us locked inside ourselves. The Buddha's teaching is, at its root, a teaching about how to stop suffering and help others do the same. So here's a fair question: why would anyone walking a path of liberation ignore a national holiday literally about people being freed from bondage? The honest answer is that we shouldn't. Juneteenth isn't a holiday that belongs only to Black Americans, any more than the Fourth of July belongs only to the founding generation. It's a marker of a particular kind of human liberation — concrete, hard-won, late in coming — and contemplatives of every background have a stake in it. There's a concept in Buddhist practice called mudita — sympathetic joy. It's the practice of taking genuine pleasure in someone else's freedom, someone else's good fortune, someone else's relief from pain. Juneteenth is a mudita holiday if there ever was one. You don't have to share an ancestry to share the joy. A quick refresher, because the history gets fuzzy fast. Chattel slavery in the United States was a system of legal ownership of human beings, passed down generationally, enforced by violence, and stitched into the economy of an entire region. The Emancipation Proclamation, signed in 1863, declared enslaved people in Confederate states free — but the proclamation only had teeth where Union forces could enforce it. Texas was the last holdout. June 19, 1865 is the day enforcement finally arrived in Galveston. Annual celebrations started that very next year. Cookouts, red drinks, music, prayer, stories passed down. The holiday has had different names — Jubilee Day, Emancipation Day, Freedom Day — and it survived through Jim Crow, through the civil rights era, through long stretches when mainstream America paid no attention at all. That endurance is part of what's worth honoring. If you're not Black and you're wondering whether Juneteenth is yours to observe, the answer from most Black communities I've spent time around is: yes, but with care. Show up. Listen more than you talk. Bring food if you're invited to a gathering. Read something you haven't read before. Sit with the discomfort of history without rushing to resolve it. A few small, sincere ways to mark the day: None of these are performative gestures if you mean them. The line between honoring and appropriating is usually drawn by intent, attention, and humility. Here's the part that gets glossed over in feel-good Juneteenth posts: legal freedom and lived freedom are not the same thing. They never have been. The Thirteenth Amendment outlawed slavery — except as punishment for a crime, a loophole that helped build the modern carceral state. Voter suppression is alive. Mass incarceration is alive. The fights over how American history gets taught in public schools are, in part, fights over whether the next generation will inherit the truth or a sanitized version of it. For anyone serious about the inner work — meditation, plant medicine, depth psychology, whatever your modality — there's a parallel here worth noticing. Personal liberation and collective liberation aren't separate projects. You can sit in ceremony all weekend and have profound experiences of unity, then walk out into a world where freedom is still unevenly distributed. The integration question isn't only “what did I learn about myself?” It's also “what am I now responsible for?” Plant-medicine traditions across the Americas have always understood this. The Indigenous and mestizo lineages that gave us ayahuasca, peyote, and psilocybin mushrooms practiced healing as a community act, not a private therapy session. The healer's job was to restore right relationship — with the body, with the land, with the people. Freedom for one was bound up with freedom for all. That's not a metaphor. It's the working theory. If you want a practice for the day itself, try this. Find ten or fifteen minutes of quiet. Sit comfortably. Bring to mind, as best you can, the specific historical fact of June 19, 1865 — soldiers reading the order aloud, people hearing for the first time that they were free. Let yourself feel whatever rises. Grief, gratitude, awkwardness, anger, relief, confusion. None of it is wrong. Then widen the circle. Bring to mind people still living under conditions that look a lot like un-freedom — incarcerated people, trafficked people, people trapped in addiction, people held inside their own trauma loops. Wish them, sincerely, the experience of release. Then bring to mind yourself, and the places you still feel bound. Wish yourself the same. That's it. No special equipment, no ceremony fee. Just a few minutes of honest attention to what liberation actually is, and who still needs it. A lot of people come to ayahuasca, psilocybin, and other plant medicines carrying personal pain — addiction, depression, the long shadows of childhood. The work is real. But the deeper the work goes, the harder it becomes to pretend that personal suffering is unrelated to the suffering around us. The medicines tend to dissolve that wall whether we want them to or not. Juneteenth is a useful reminder, on the calendar, that liberation has a history. People fought for it, died for it, waited two and a half years past the official decree for word to reach them. The freedoms we get to play with in a ceremonial space — the freedom to look inside, to sit with hard things, to imagine ourselves differently — exist on top of that history, not separate from it. If exploring that kind of inner liberation through plant medicine is something you've been quietly considering, a range of curated retreats across the Americas can be browsed on our marketplace here. Whatever you choose, mark the day. Eat something good. Call someone you love. Sit with the long, uneven, still-unfinished work of being free.
When Did Ayahuasca Become a Luxury Only the Rich Can Afford?
Somewhere between the first time a Western seeker stumbled into a Shipibo maloca in the early 2000s and right now, ayahuasca got expensive. Not slightly expensive. Five-figure-package, white-glove-airport-pickup, organic-chef-prepared, infinity-pool-overlooking-the-Sacred-Valley expensive. And if you've spent any time researching retreats lately, you've probably noticed the same thing I have: the people who arguably need this medicine the most — folks crawling out of addiction, grinding through depression, sitting on years of unprocessed trauma — often can't afford it. So what happened? When did the vine that grew wild behind a curandero's house become a luxury product with a waiting list and a wellness concierge? Let's get into it honestly, because the people quietly considering whether to book an ayahuasca retreat deserve a clear-eyed answer, not a brochure. For most of its known history, ayahuasca wasn't a product at all. It was a practice. Curanderos and ayahuasqueros across the Amazon basin — Shipibo, Shuar, Asháninka, mestizo lineages — worked with the brew as part of a broader healing tradition. People paid what they could. Sometimes that was a chicken, a sack of rice, a few soles, or nothing at all if they were sick and broke. The Western pilgrimage started small. In the 1990s and early 2000s a trickle of seekers, anthropologists, and recovering addicts found their way to Iquitos or Pucallpa, often by word of mouth, and sat in ceremonies that cost maybe twenty or thirty dollars a night, sometimes less. Plenty of those early arrangements were informal, occasionally chaotic, and not always safe — but they were accessible. Then came the documentaries. Then the celebrity ayahuasca confessions. Then the wave of articles about psychedelic healing for addiction and PTSD. Then the investors. Somewhere in that decade-long arc, the market figured out that wealthy, miserable Westerners would pay a lot to feel whole again. And like every wellness category before it — yoga, meditation, breathwork, ice baths — the prices climbed to meet what the top of the market would bear. Here's the uncomfortable breakdown. A week-long ayahuasca retreat in Peru or Costa Rica now commonly runs between three and seven thousand dollars, and the boutique end goes well past ten. That money is not, mostly, going to the medicine itself. The brew is cheap to make. The vine and chacruna leaf grow in the jungle. What you're paying for is roughly this: None of that is automatically bad. A safe, comfortable, well-run retreat with proper screening, a medical professional on call, and integration support genuinely costs more to operate than a hut in the jungle with one shaman and a kettle. The question is whether what you're paying maps to what you're getting — and whether the curanderos pouring the medicine are seeing a fair cut. Often they aren't. Short answer: yes, but you have to work harder for it, and you have to accept more risk. There's a whole tier of the ayahuasca world that doesn't show up in the top Google results because it doesn't run paid ads. Smaller centers near Iquitos, Tarapoto, and Pucallpa still offer week-long stays in the $500–$1,500 range. Some are excellent. Some are sketchy. The reputable ones tend to be Shipibo- or mestizo-run, with modest accommodations, simple food, and a focus on the work rather than the wallpaper. You find them through forums, word of mouth, and patient digging — not glossy landing pages. The trade-off is real. Cheaper retreats often have less rigorous medical screening, fewer English-speaking staff, no formal integration program, and less institutional accountability if something goes wrong. That doesn't make them dangerous by default — many have run safely for decades — but it does mean you carry more of the responsibility for vetting them yourself. A few practical avenues if cost is the wall standing between you and this work: If you're sitting at your laptop with a tab open to a $5,800 retreat in the Sacred Valley and another tab open to your bank account, here's what I'd actually say. Price is not a proxy for quality. I've sat in cheap ceremonies that were profoundly skillful and expensive ones that felt like spiritual Disneyland. What matters is the lineage and experience of whoever is pouring the medicine, the integrity of the screening process (a place that doesn't ask about your SSRIs or heart conditions is a red flag, regardless of cost), the ratio of facilitators to participants, and whether there's any real plan for what happens after you fly home. Integration is where the work actually lands, and it's often the first thing cut from budget retreats and the most overpriced thing at luxury ones. If you're considering plant medicine for addiction, severe depression, or trauma, the stakes of choosing well go up sharply. This isn't a wellness weekend — it's a serious intervention, and serious interventions deserve serious vetting. Talk to former participants. Ask uncomfortable questions. Read the bad reviews, not just the testimonials. If a retreat won't connect you with a recent attendee, that tells you something. And don't let the marketing convince you that the only legitimate way to meet this medicine is through a curated package with a sound-healing add-on. Some of the most transformative ceremonies in history happened in a dirt-floor hut with one shaman, one icaro, and one very scared seeker. The medicine doesn't care about your thread count. What does it mean that a healing tradition born among people with very little has become, in its most visible form, something mostly available to people with a lot? The honest answer is that it's a familiar story — yoga, mindfulness, indigenous foods, ceremonial cacao — and it doesn't have a clean ending. Some of the money flowing into the Amazon is genuinely helping communities. Some of it is just extraction in nicer clothes. The retreats that take this seriously are usually the ones willing to talk about it openly, fund reciprocity programs, pay their indigenous staff equitably, and not pretend the whole thing is just commerce. As a prospective participant, you have more leverage than you think. Ask retreats how much of their fee goes to the curanderos. Ask what they give back to the communities the medicine comes from. The answers will tell you a lot about who you're really handing your money — and your psyche — over to. If something in this piece is nudging you toward taking the next step, a range of carefully vetted ayahuasca retreats across price points can be browsed on our marketplace here. Take your time. The medicine isn't going anywhere, and the right container is worth waiting for.
Mary Oliver, Attention, and Why Poetry Still Matters in the Quiet Hours Before Ceremony
There's a poem that keeps turning up in retreat centers. You'll find it scrawled in the back of someone's journal at breakfast on day three. Taped to the wall of a maloca in the Sacred Valley. Read aloud, sometimes shakily, during an integration circle when nobody knows quite how to begin. It's Mary Oliver's The Summer Day, and the final line — what is it you plan to do with your one wild and precious life? — has a way of cutting through the noise that ceremony tends to leave behind. I want to talk about why this poem keeps showing up in the world of ayahuasca, psilocybin, and other plant medicines. Not because Oliver herself wrote about psychedelics — she didn't. But because what she's pointing at is the exact same territory the medicines crack open: the quality of attention you bring to being alive, and what you intend to do with the days you still have. If you haven't read it, the structure is simple. Oliver opens with a child's question — who made the world, who made the swan and the bear and this particular grasshopper eating sugar from her palm. She describes the insect in close, almost tender detail. Its complicated eyes. Its pale forearms. The way it washes its face before flying off. Then she shifts. She admits she doesn't know what a prayer is. But she does know how to pay attention, how to fall down in the grass, how to be idle and blessed. And then comes the closer: Doesn't everything die at last, and too soon? Tell me, what is it you plan to do with your one wild and precious life? That's the whole thing. Maybe twenty lines. Nothing fancy. And yet people carry it around with them for decades. Anyone who's sat in a serious ceremony — ayahuasca, San Pedro, psilocybin, ibogaine — knows the feeling of returning. You come back into your body and your kitchen and your job and your relationships, and something has shifted. Sometimes it's enormous. Sometimes it's small. But the shift almost always involves a sharper relationship to time. You suddenly notice you've been sleepwalking through your own life. The medicine pulled back a curtain, and now you can't quite un-see what was behind it. Oliver's poem does something similar, only without the brew. She's not asking a metaphysical question. She's asking a practical one. You're going to die. So am I. So is everyone. Given that — what do you actually plan to do? This is the same question the master plants ask. People who come to plant medicine for addiction recovery, depression, trauma, or just a sense of being stuck — they often describe the experience as a confrontation with this exact problem. Not the cosmic stuff. The specific, granular stuff. Are you going to keep drinking? Are you going to keep avoiding that conversation with your father? Are you going to keep waiting for permission to live the life you actually want? There's a line in the middle of the poem that I think gets undervalued. Oliver writes that she doesn't know what a prayer is, but she knows how to pay attention. She offers attention as the substitute for prayer — or maybe as prayer itself. This is worth sitting with if you're considering a retreat. Most facilitators I've spoken to, across traditions, will tell you that the medicine isn't really the medicine. The medicine is the attention you learn to bring. Ayahuasca, San Pedro, psilocybin — these are amplifiers. They turn the volume way up on whatever you're already paying attention to, whether that's an old grief, a buried memory, the texture of the wind moving through the leaves, or the quality of the silence between the icaros. The work, before and after, is learning how to keep that dial turned up when you're back in ordinary life. That's where the poem becomes practical. How to fall down in the grass, how to kneel down in the grass, how to be idle and blessed. These are training instructions, not just pretty phrases. If you're in the research phase — weighing whether to book, comparing centers, reading reviews and trying to figure out if any of this is actually for you — I'd suggest something modest. Print the poem. Carry it with you for a week. Read it once in the morning and once before bed. Don't analyze it. Just let the final question sit there. Here are a few things people often notice when they do this: None of this replaces the actual preparation work — the dietary restrictions, the medical screening, the conversations with facilitators about your history and intentions. But it gets you closer to the doorway. It softens you. I'll offer one caution. Oliver's poem is so quotable that it sometimes gets used as decoration — printed on tote bags, screen-printed onto candles, dropped into Instagram captions next to photos of someone doing yoga at sunset. There's nothing wrong with that, exactly. But it can hollow the words out. The same hollowing-out can happen with plant medicine. People come back from a ceremony with profound material, and within a month it's been reduced to a handful of catchphrases. I learned to surrender. I met my inner child. I am pure love. Fine. Maybe. But what did you actually do on Tuesday? Did you call the person you needed to call? Did you stop the thing that's been killing you? Did you start the thing you've been afraid to start? The poem and the medicine both lose their power when they get turned into slogans. The question Oliver poses isn't supposed to feel inspirational. It's supposed to feel slightly threatening. Like a friend who loves you enough to ask the question you've been avoiding. If you're reading this, there's a reasonable chance you're somewhere in the long, quiet process of considering a plant medicine retreat. You've watched the documentaries. You've read the trip reports. Maybe you've talked to one or two people who've done it. You're trying to figure out whether this is the right thing for you, or whether it's just another shiny object you're hoping will fix what's been broken for a long time. The poem can't answer that for you. Neither can I. But the question at the end of it — the one Oliver leaves hanging — is, I think, the right question to bring with you into any decision about psychedelic healing. Not will this fix me. Not will this make me happy. But: given that the time is finite, given that everything dies at last and too soon, what do you actually plan to do? If the answer involves stepping toward a retreat, do it with care. Choose facilitators who screen you properly, who don't promise outcomes, who take integration seriously. For readers who want to take this further, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. And whatever you decide — go or don't go — keep the poem somewhere you'll see it. The grasshopper, the grass, the impossible last line. They have a way of staying useful.
Remembering Robert Thurman: The Scholar Who Bridged Tibet and the West
When Robert Thurman passed in early 2026, the obituaries reached for the easy descriptors. Father of Uma. First American monk in the Tibetan tradition. Lifelong friend of the Dalai Lama. All true. All incomplete. The man was bigger than the trivia. For five decades he argued — loudly, often hilariously, occasionally to the irritation of his peers — that the West had picked up the wrong end of the stick when it came to Buddhism. He thought we'd fallen in love with the cushion and skipped the books. He thought meditation without study was, in his own words, a bunch of nonsense. And he spent his career trying to fix that. Whether you ever sat in one of his lectures at Columbia or read his translation of the Tibetan Book of the Dead on a long flight somewhere, his fingerprints are probably on the version of Tibetan Buddhism you encountered. Worth understanding why. Thurman's path into Buddhism wasn't tidy. In 1961, at age twenty, he lost his left eye in a freak accident involving a racecar and a jack. The prosthetic he wore for the rest of his life became, in a strange way, part of the lore — a reminder that the man who would later translate sutras about impermanence had learned a few things about it the hard way. A few years later, in 1964, he met Geshe Wangyal, a Mongolian lama who'd settled in New Jersey. Wangyal sent him to India. There, at twenty-three, Thurman met the twenty-nine-year-old Dalai Lama, and the two struck up the kind of friendship that lasted six decades. In 1965, the Dalai Lama ordained him — the first American to take robes in the Tibetan tradition. Thurman gave them up two years later to marry Nena von Schlebrügge, a Swedish model with a serious interest in dharma. That trajectory — monk, ex-monk, husband, father, professor — sounds like a contradiction. Thurman insisted it wasn't. He'd often say his wife became his third great teacher. The household he built with Nena in Woodstock, New York, ended up being a small embassy for Tibetan culture in America, complete with sacred statues, dandelion tea, and decades of visiting lamas. Thurman had a critique he repeated for forty years, and it's worth pausing on because it matters to anyone drawn to contemplative life today — including anyone weighing a meditation retreat, a psychedelic ceremony, or any other route into the inner work. His argument, roughly: meditation alone won't get you there. Not because the practice is empty, but because without study — without actually learning the philosophy of mind that the tradition spent two thousand years working out — you don't know what you're looking at when something interesting happens on the cushion. You mistake a quiet mind for enlightenment. You mistake feeling good for insight. You stop just short of the point. He put it bluntly in interviews: the buzz you get from shutting down your thinking process isn't enlightenment. It's just a buzz. Pleasant, sometimes useful, but not the prize the texts are pointing at. The prize requires knowing something — about the nature of self, about karma, about how perception constructs the world you think you're living in. This is an unfashionable view in much of contemporary Western practice. The mindfulness boom has largely stripped Buddhist meditation of its metaphysical content and sold the technique on its own. Thurman wasn't against secular mindfulness — he said he was fine with it. He just didn't want anyone confusing it with the full path. When Thurman wrote his Harvard PhD thesis, he coined the term Buddhology on a whim, on the form itself. The label mattered. He wasn't studying Buddhists the way an anthropologist studies a distant tribe. He was a Buddhist studying Buddhism from inside, with all the philosophical seriousness the tradition deserved. That stance got him in trouble with the religious-studies establishment. Colleagues wrote letters opposing his hiring. The unspoken rule was that a white American academic could analyze Buddhism, but shouldn't be one. Thurman ignored them. He took his post at Columbia in 1988 and proceeded to teach Indo-Tibetan studies there for thirty years, packing lecture halls and producing a generation of serious scholars. His colleague Peter Awn, then chair of Columbia's religion department, said the thing that impressed him most wasn't Thurman's celebrity or his Hollywood connections. It was the quality of the graduate students he turned out. Philosophically rigorous, intellectually fearless, willing to take Buddhist ideas seriously as ideas rather than as exotic cultural artifacts. Alongside his academic work, Thurman spent decades building institutions. In 1986, at the Dalai Lama's request, he cofounded Tibet House in New York City with Richard Gere and composer Philip Glass. The mission was simple and urgent: preserve Tibetan culture at a moment when the Chinese occupation was actively erasing it inside Tibet itself. Later came Menla, the retreat center in the Catskills that the Thurmans built into a place where Tibetan medicine, meditation, and culture could be encountered firsthand. The story of how they acquired the property has a kind of mythic shape to it — Nena meeting the right person on a pilgrimage to Mount Kailash, the property turning out to be twenty minutes from their Woodstock home. Thurman told that story with relish. He always sounded a little surprised by the way things had unfolded for him, as if half-expecting someone to point out the joke. The institutions were practical answers to a practical problem: how do you transmit a living tradition across an ocean and a century, when the culture that grew it is under threat? Thurman's answer was that you do it carefully, slowly, and with both scholarship and devotion. You don't shortcut it. You don't reduce it to a wellness product. Plenty of readers who land on a piece like this are doing so because they're considering a retreat — maybe a meditation intensive, maybe an ayahuasca ceremony, maybe something in between. Thurman's life has something useful to say to that decision, even though his own tradition didn't involve psychedelics. A few takeaways worth holding onto: Thurman walked a strange line his whole life — public intellectual, devout practitioner, friend of celebrities, translator of ancient texts, husband, father, advocate for an occupied nation. He didn't think any of those roles canceled the others out. He thought a good life was wide enough to hold them all, provided you did the reading. If something in his story has stirred the part of you that's been quietly wondering whether to take your own practice further, plenty of meditation and plant-medicine retreats that honor that same depth-first approach can be browsed on our marketplace here. Pick one that asks more of you than a weekend buzz. That, more than anything, is what Thurman spent his life arguing for.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Psychedelic Policy in 2026: MDMA Trials, Australia's Access Rules, and What It Means for Retreat-Seekers
If you've been quietly researching a psychedelic retreat over the past year — maybe an ayahuasca journey for old trauma, or a psilocybin program to interrupt a depressive spiral — you've probably noticed the landscape moving fast. Laws are shifting. New trials are launching. Countries you wouldn't have guessed are quietly building legal access pathways. And it's getting hard to tell what actually matters for someone weighing a real decision. So here's a grounded look at where psychedelics, plant medicine, and addiction research stand right now in 2026 — and what the recent wave of policy and clinical news actually means if you're thinking about sitting in ceremony or booking a retreat. No hype. No prophecy. Just the stuff worth knowing. The story of the last twelve months isn't a single breakthrough. It's a slow drip of small, real-world shifts: a federal lobbying disclosure here, a new MDMA study there, a regulator quietly loosening eligibility somewhere else. Taken together, these moves are pulling psychedelic-assisted care a little further out of the underground and a little closer to mainstream mental health treatment. For someone considering a retreat, this matters in two ways. First, the legal and clinical conversation around psychedelics affects how seriously friends, family, and your own doctor will take your decision. Second, the research now coming out gives you better questions to ask any retreat or therapist — about screening, integration, dose, and what reasonable outcomes actually look like. None of this means a clinical psilocybin trial in Stockholm is the same thing as a five-night ayahuasca dieta in the Sacred Valley. They're not. But the science and the ceremonial worlds are no longer running on completely separate tracks, and the cross-pollination is informing both. Federal lobbying records from the first quarter of 2026 show what's been true for a couple of years now: psychedelic policy in the U.S. is being pushed forward, more than anything else, by advocates focused on veterans and treatment-resistant PTSD. That's not a coincidence. It's the cleanest political story available — people who served, came home wounded in ways the VA's standard toolkit hasn't fixed, and found something that helped. This pressure has translated into real movement. The Department of Veterans Affairs has continued rolling out MDMA-assisted therapy trials inside its own system — including a trial first announced at the tail end of 2024 that has now actually launched. The framing matters: when the VA studies a substance, even cautiously, it slowly normalizes the idea that psychedelics belong in a clinical conversation rather than a moral one. For retreat-seekers, the practical upshot is small but real. If you're a veteran, or work with veterans, the path to legal psychedelic-assisted care inside a clinical setting is genuinely getting wider. For everyone else, it remains mostly a matter of waiting for state programs, traveling to a legal jurisdiction, or pursuing ceremony through traditional or quasi-legal frameworks abroad. One of the more interesting research stories of the year is a study, funded in part by the State of Maryland and the nonprofit Reason for Hope, comparing group MDMA-assisted therapy against the more familiar one-on-one model for PTSD. The Sunstone Therapies team is running it. The question they're asking — does group work as well as individual? — has enormous implications for cost, access, and the shape of future legal programs. If you've ever sat in a circle at a retreat, none of this will feel novel. Group ceremony is the historical norm for ayahuasca, San Pedro, and most traditional plant-medicine practice. The clinical world is, in a sense, catching up to something the indigenous world figured out a long time ago: that healing in the company of others has its own particular power. Witness matters. So does the held container. Why does this study matter for you? Because if group-format psychedelic therapy proves comparably effective, the economics of legal access shift dramatically. A six-person psilocybin group is far more affordable than a six-hour solo session with two therapists. That changes what kinds of programs become possible. And it lends quiet validation to the group format many existing retreats already use. Australia became the first country to formally reclassify psilocybin and MDMA for prescribed therapeutic use back in 2023, but the rollout has been famously cautious — high cost, narrow eligibility, paperwork that scared off most candidates. This year, regulators have loosened several elements of that pathway, making it modestly easier for authorised psychiatrists to treat patients with treatment-resistant depression or PTSD using psilocybin or MDMA. Don't read this as Australia becoming a psychedelic free-for-all. It hasn't. The framework is still tightly medical, still expensive, and still requires you to fit a specific clinical profile. But it's becoming a useful reference point for how a regulated psychedelic-therapy system can evolve when policymakers actually try to build one rather than wait for the federal level to move. If you're an Australian reader specifically weighing your options, this is the moment to talk to a psychiatrist who works in the space — the bar to entry has come down, even if it's nowhere near low. If you're elsewhere, the Australian experiment is the closest thing we have to a real-world test of medicalized psychedelic care, and it's worth watching. Two studies are worth pulling out of the recent wave. A Swedish trial reported an antidepressant effect of psilocybin in patients with major depressive disorder — adding to a now-substantial body of evidence that a single high-dose session, paired with appropriate psychological support, can produce meaningful reductions in depression scores. Separately, follow-up data from the German EPIsoDE trial suggest the antidepressant response to psilocybin can be sustained over time, not just measured in the first few weeks. I want to be careful here. "Sustained" in a clinical context usually means months, not forever. Some participants relapse. Some don't respond at all. The research consistently shows that integration — the unglamorous work of making sense of what happened and changing what you do afterward — is what separates lasting benefit from a fascinating Tuesday afternoon. What this means practically for anyone considering a retreat: A new UK poll found broad public support for regulated psilocybin access for people with serious mental health conditions. This tracks with similar surveys across North America and parts of Europe — people are increasingly comfortable with the idea that psychedelics belong in the toolkit, even when their own governments aren't yet. This gap between public opinion and policy is, I'd argue, the most interesting feature of the current moment. It's why so many retreats exist in jurisdictional grey zones, why ceremonies continue to grow despite no federal legal framework in the U.S., and why so many people you'd never expect — schoolteachers, executives, retired nurses — are quietly researching plant medicine for addiction, depression, or simply for the feeling of being stuck. Here's the thing: news cycles about MDMA trials and Australian regulations can feel a long way from your actual question, which is probably some version of "should I do this, and where, and is it safe?" Let me try to bridge that. First, the policy momentum is real but slow. If you're suffering now and waiting for legal access in your home country, that wait might be years. Many people who choose ayahuasca, psilocybin, or ibogaine retreats abroad are making a clear-eyed calculation: the option exists, the research is increasingly supportive, and they're tired of waiting. Second, the clinical research is giving you a vocabulary for evaluating a retreat. Ask about screening. Ask about medical history intake. Ask about facilitator training and supervision ratios. Ask what happens if you have a difficult night — because difficult nights happen, and the quality of the response is what separates a sound retreat from a risky one. Third, the master plants — ayahuasca, San Pedro, iboga, tobacco in its ceremonial form — operate within traditions that long predate any clinical trial. The science is catching up to something old. If you go that route, take both seriously: the research-backed protocols for safety and the lineage that gives the ceremony its form. For readers ready to take the question from "should I?" to "where might I?", a curated range of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. The most useful next step isn't necessarily booking — it's seeing what's actually out there and what specific programs offer, so the abstract decision becomes concrete. The psychedelic moment we're living through isn't going to peak and pass. It's restructuring how mental health, addiction recovery, and self-exploration are talked about. Whether you eventually sit in ceremony or simply keep reading and thinking, you're paying attention at the right time.
Where U.S. Psychedelic Laws Actually Stand in 2026: A State-by-State Read
If you're sitting on the fence about a psychedelic retreat — maybe an ayahuasca week in Peru, maybe an ibogaine program in Mexico, maybe something closer to home — the legal weather report matters more than most retreat-seekers realize. Where a substance sits on the law books shapes who gets to offer it, how much it costs, and whether the person pouring your cup has a real license or a flimsy disclaimer. So here's a plain-English read on where U.S. psychedelics policy stood as legislatures wound down their 2026 sessions. Out of 115 psychedelics-related bills tracked this year — 108 at the state level, 7 federal — seventeen distinct measures have been signed into law. Two were vetoed. Forty-four died quietly with their sessions. About fifty are still technically alive in legislatures that haven't gaveled out. More than a quarter of this year's signings happened in a single month: May. That's the headline. The story underneath it is more interesting. Psilocybin still leads the raw count of enacted bills, but most of those wins are trigger laws — technical rescheduling measures that flip a switch the moment the FDA approves a psilocybin-based medicine. They matter, but they're plumbing. They don't change much for someone considering a retreat next month. Ibogaine is the genuinely surprising story. Twenty-five ibogaine-focused bills were introduced across fourteen states this year. Six are now law. A seventh — New Hampshire's HB1772 — sits one vote from passage. If that lands, the success rate for ibogaine bills clears 25%, which is well above the rate for psychedelic bills as a whole. Why ibogaine, why now? Three reasons keep coming up in legislative testimony: For readers weighing ibogaine specifically — usually because nothing else has touched their addiction or depression — the practical takeaway is that the U.S. landscape is moving, but slowly. Most legitimate ibogaine treatment still happens in Mexico, Costa Rica, or Portugal. Domestic clinical access is years away from anything resembling routine. Rather than march through every bill number, here's the shape of the month in plain language. California saw movement on regulated-access frameworks that have been circulating for years now. The state keeps inching toward something — a therapist-supervised model, probably psilocybin-first — without quite getting there. If you're a Californian who's been waiting to do this work locally, the honest read is: keep waiting, or travel. Colorado, already the regulated-access pioneer with its Natural Medicine program, continued to refine the operational rules. The first licensed healing centers have been seating clients, prices are landing in the $1,500 to $3,000 range per session depending on the provider, and the early reports from facilitators are roughly what you'd expect: lots of demand, complicated insurance picture, real clinical results mixed in with the predictable growing pains. Connecticut, Hawaii, Illinois, and Massachusetts each moved bills in committee that focus on research and limited therapeutic access — slow, deliberate, no fireworks. Georgia and Louisiana saw ibogaine-specific measures advance, mostly framed around veteran access and opioid use disorder research. Michigan and Missouri had bills die in chamber, which is a polite way of saying the votes weren't there yet. Oklahoma and Tennessee both moved on the research-funding angle. North Carolina had a measure progress further than most observers expected. New Hampshire — small state, outsized influence on this issue — kept HB1772 alive heading into June. At the federal level, the seven bills tracked include the usual mix of veteran-access carve-outs, research authorizations, and rescheduling proposals. Nothing has passed. Nothing is close to passing. Federal reform in this space remains a turtle race. Three practical implications if you're researching plant medicine right now. First, legality is not the same as safety. A retreat operating in a country where ayahuasca is legal isn't automatically run by competent people. Conversely, an underground psilocybin sitter in a state where it's still Schedule I might be the most skilled facilitator in your region. Use the legal picture as one data point, not a verdict. Second, the U.S. patchwork is going to confuse you, and that's reasonable. Oregon and Colorado have regulated psilocybin access. Several cities (Denver, Oakland, Detroit, Seattle, Cambridge, Somerville, Washington D.C. by ballot) have decriminalized at the local level. Most other states treat psilocybin as a Schedule I controlled substance. Ayahuasca occupies a strange middle ground — the brew itself is Schedule I federally, but the UDV and Santo Daime churches won religious-use exemptions in the 2000s. Ibogaine remains Schedule I with no domestic legal pathway outside of narrow research contexts. Third, the offshore retreat economy isn't going anywhere. Peru, Costa Rica, Brazil, the Netherlands (for psilocybin truffles), Jamaica, and Mexico still host the vast majority of ceremonies that Americans attend. Policy reform at home will, over the next five to ten years, build a domestic alternative. It will not replace the traditional Amazonian retreat model, and it shouldn't — those are different rooms with different medicine. A few honest questions to put to any operation you're considering, with the policy backdrop in mind: None of this is meant to scare you off. People genuinely benefit from these experiences — that's why the policy reform is happening at all. It's meant to push you toward the questions that matter while the legal scaffolding around this work is still being built. Several legislatures haven't adjourned yet, which means the year-end tally will shift. Watch New Hampshire on ibogaine. Watch a handful of states with carryover sessions where psilocybin therapy bills are still technically alive. At the federal level, the most realistic near-term reform isn't broad rescheduling — it's targeted veteran-access language quietly attached to a defense authorization bill. That's how policy actually moves in Washington: through side doors. Internationally, Australia's prescribed-MDMA-and-psilocybin pathway continues to produce real-world data. Germany has begun psilocybin compassionate use for treatment-resistant depression. Canada's Special Access Program keeps approving individual cases. The global picture is moving faster than the U.S. picture, which is part of why the offshore retreat model remains the default for most Americans seeking this work. If you've been quietly researching plant medicine because something in your life isn't moving — a depression that hasn't lifted, an addiction the patches haven't touched, a layer of grief that's outlasted talk therapy — the legal news is mostly good. The doors are opening, even if slowly, and the underground is becoming less underground every year. For readers who want to take the next step, a range of curated ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine will still be here when you're ready, and so will the law — probably a little friendlier than it was when you started reading.
Psilocybin in Germany: Inside Europe's First Compassionate Use Program
Something happened in Germany last summer that most people outside the psychedelic research world missed entirely. The country's drug regulator, BfArM, quietly approved the European Union's first compassionate use pathway for psilocybin. No press conference. No splashy announcement. Just a regulatory door opening — and a handful of patients suddenly able to access something that, almost everywhere else on the continent, remains locked behind clinical trial walls. If you're someone who's been tracking the slow march of psychedelic medicine toward legitimacy — or quietly wondering whether psilocybin might help with depression that hasn't budged for years — this is a story worth understanding. It's messy, it's promising, and it tells you a lot about how plant medicine and psychedelic-assisted therapy might actually arrive in mainstream care. Spoiler: it won't look like a retreat in the Amazon. Compassionate use is a regulatory pathway that lets doctors prescribe an unapproved drug to patients who've run out of other options. It exists in the gap between "this looks promising in trials" and "this is officially approved medicine". For psilocybin — still classified as a controlled substance in most jurisdictions — that gap has been the only legal route to treatment outside a study protocol. Germany now has two centres authorised to offer this. One is OVID Clinic Berlin, a private operation in the capital co-led by Dr. Andrea Jungaberle and Dr. Gerhard Gründer. The other is the Central Institute of Mental Health in Mannheim, a public university hospital where researcher and psychotherapist Lea Mertens is helping to build the program from the ground up. The two sites couldn't be more different in flavour — one is a focused private clinic, the other is, in Mertens' own words, a big machine — but they're both working under the same framework. The legal basis came largely from the EPIsoDE trial, a German clinical study on psilocybin for treatment-resistant depression. Mertens is first author on the trial's primary publications, including the long-term follow-up. The data was strong enough, and the patient need acute enough, that the regulator agreed: certain people shouldn't have to wait until full marketing authorisation lands somewhere around the end of this decade. This is where it gets practical. Compassionate use in Germany is aimed at patients with treatment-resistant depression — meaning they've tried multiple antidepressants and other interventions without meaningful relief. It isn't a wellness option. It isn't open to the curious. It's a last-line therapy, and the screening reflects that. The money question is the one most readers actually care about. In Germany, roughly 90% of the population is on statutory public insurance, and around 10% — including civil servants and higher earners — are on private insurance. OVID has worked out an arrangement where the compassionate use treatment itself is bundled into a day clinic stay. Patients on private insurance pay nothing extra for the psilocybin component; the insurance covers the clinical day rate. The clinic has even negotiated a fast-track agreement with Germany's largest private insurer, promising approval within a week when granted. Mannheim is going further. As a public hospital, their goal is full public insurance coverage. If a patient is treated as an inpatient, the standard daily copay applies regardless of what's being administered, which means psilocybin therapy falls under the existing reimbursement structure almost by default. The team is also pushing for outpatient approval, which would be cheaper, easier to schedule, and less likely to raise questions from public payers. Meanwhile, the institute is sitting on a waiting list of around 700 patients who've already raised their hands. If you've been researching plant medicine, you've probably looked at retreats in Jamaica, the Netherlands, Peru, or Costa Rica — places where psilocybin truffles or ayahuasca ceremonies operate in legal grey zones or established traditional frameworks. The German model is a different animal entirely. Here's how the differences shake out: Neither model is inherently better. They serve different people with different needs. Someone with severe, suicidal-level depression who's failed four antidepressants probably belongs in a clinical setting with medical backup. Someone working through grief, stuck life patterns, or existential drift might be better served by a well-run ceremonial retreat where the container is built around meaning-making rather than symptom reduction. Knowing which you are is half the work of choosing well. One of the more interesting things Mertens and Jungaberle have pointed to is the flexibility that compassionate use offers compared with a clinical trial. In a trial, every variable is locked: dose, number of sessions, therapist contact hours, music, the exact wording of the preparation protocol. That rigidity is necessary for clean data, but it's a terrible fit for real-world therapy, where one patient might need two sessions and another might need four, and where the integration work can stretch over months. Compassionate use lets clinicians treat the patient in front of them. If someone needs a lower starting dose because they're on a complicated medication regimen, fine. If someone benefits from extra integration sessions, that's a clinical decision rather than a protocol violation. This is closer to how psychedelic therapy will probably look once it's fully approved — and Germany is building that operational muscle now, while the rest of Europe watches. There's also a quiet political dimension. By running this through public hospitals and getting public insurers to pay, the Mannheim team is establishing precedent. If statutory insurance covers psilocybin therapy for treatment-resistant depression in 2026, it becomes much harder to argue, when full approval lands, that it shouldn't be reimbursed then too. Access begets access. Realistically, most readers won't qualify for the German program. The bar is high, the waiting lists are long, and unless you live in Germany or can establish care there, it's not a practical option. But the existence of this pathway tells you something important about the direction of travel for psychedelic-assisted recovery — and that should inform how you think about your own decisions. A few honest things to sit with if you're weighing your options: What Germany is doing is unglamorous and important. It's the slow, bureaucratic work of building a legitimate clinical pathway for a substance that, until recently, sat firmly in the counterculture. The patients getting treated at OVID and Mannheim aren't headed for spiritual awakening — they're trying to climb out of years of depression that nothing else has touched. And the program is being designed so that when it works, it can scale. For anyone watching the psychedelic field, this is the model worth tracking. Not because clinical psilocybin will or should replace traditional plant-medicine retreats — they answer different questions — but because legitimate medical access changes the cultural conversation. It makes it easier for the family doctor to talk about psychedelics without flinching. It gives insurance companies a framework for reimbursement. It moves the whole field forward by inches, then feet. If you've read this far and you're quietly weighing whether some form of psychedelic experience belongs in your own healing — whether for depression, addiction, trauma, or a creeping sense of stuckness — the honest advice is: take your time, screen the provider as hard as they screen you, and don't romanticise the medicine. For readers who want to take this further, a curated selection of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever path you choose, the best outcomes seem to come to people who arrive prepared, supported, and a little skeptical — in the good way.
Group Psychedelic Therapy: Why Collective Healing Is Reshaping Plant Medicine
Walk into any traditional ayahuasca ceremony in the Amazon and you'll notice something the modern clinical model still struggles to replicate: nobody's drinking alone. There's a circle. A shared darkness. A song that holds everyone in it. For thousands of years, this is what plant medicine has looked like — collective, relational, sung into being by people who showed up together. Now, somewhat ironically, Western researchers are catching up. Group-based psychedelic therapy is having a moment in clinical journals, in psychiatric conferences, and in the strategy decks of companies thinking about how to actually deliver psychedelics to the millions of people who might benefit. If you're researching a retreat right now — weighing whether to sit in a circle of strangers or pay for a one-on-one session — this shift matters more than it might seem. The reason is partly practical and partly philosophical. Practically, there simply aren't enough trained facilitators to deliver one-on-one psychedelic therapy at any meaningful scale. If psilocybin gets approved for treatment-resistant depression and even a fraction of eligible patients show interest, the math doesn't work. You can't 1:1 your way out of a mental health crisis affecting tens of millions. Philosophically, though, something deeper is going on. Researchers like Dr. Leor Roseman have been exploring what he calls communitas — that strange, electric sense of belonging that can arise when people take psychedelics together. His work suggests the collective container isn't just a logistical workaround. It might be doing something the solo experience can't. Loneliness, after all, is now considered a public health emergency in much of the Western world. If a chunk of our psychological suffering comes from disconnection, then maybe healing it requires reconnection — not just more introspection on a therapist's couch. This isn't a new idea. In the mid-twentieth century, before the legal shutters came down, clinicians were already running LSD groups for alcohol use disorder and various neurotic conditions. The plant-medicine traditions of the Amazon, the Mazatec mushroom velada, the Native American Church's peyote meetings — all of these are group rituals. The lone-seeker-in-a-recliner model is actually the historical anomaly. If you've never been in one, here's roughly what to expect. A group ceremony — whether ayahuasca in Peru, psilocybin in a legal Dutch retreat, or a clinical trial format — typically gathers somewhere between six and twenty participants. You arrive a day or two early. There's preparation: conversations about intention, a medical screening, sometimes a dietary protocol. You meet the people you'll be journeying with. The dosing itself happens in a shared space. In traditional ayahuasca work, that's often a maloca — a thatched-roof ceremonial structure — with mats arranged around the perimeter and curanderos working their icaros (the songs sung over each participant). In a clinical psilocybin group, it's usually a quieter, more living-room-feeling space, eye masks on, curated music piped through speakers, two or three facilitators circulating. Either way, you go inward. Mostly. But the presence of others — their breathing, their occasional crying, the song carrying the whole room — becomes part of the journey. The integration days afterward are where the group dimension really earns its keep. Sitting in a circle with five other people who just had a similar experience, hearing what came up for them, watching someone else articulate something you couldn't quite name in yourself — that's a kind of mirror that solo integration can't easily provide. People often describe leaving these retreats with a small network of others who understand what they saw. That's not nothing. Group containers aren't for everyone, and any facilitator worth their salt will tell you so. Here are the questions actually worth sitting with before you book: One of the more interesting tensions in the current psychedelic moment is between the indigenous understanding of ayahuasca, San Pedro, peyote, and tobacco as master plants — sentient teachers with whom one builds relationship over years — and the Western drive to standardise, dose, and scale these substances into clinical products. Group ceremonies, when held in traditional or traditionally-informed settings, preserve more of that relational quality. The plant is treated as a teacher in the room, not a compound being delivered. That distinction matters when you're choosing a retreat. A clinical psilocybin group in Oregon and an ayahuasca circle led by a Shipibo maestra in the Peruvian Amazon are both group psychedelic experiences. But they're aiming at different things, drawing on different lineages, and asking different things of the participant. Neither is better in some absolute sense. They're just different doors into different rooms. If you're drawn toward the traditional end of the spectrum, look for retreats that work with established lineages — Shipibo, Quechua, Huachuma traditions in South America, or the Bwiti tradition for ibogaine in Gabon. Ask who the facilitators trained with, for how long, and what their relationship to the source community looks like. If you're drawn toward the clinical end, look for facilitators with formal psychotherapeutic training, transparent safety protocols, and a clear preparation and integration arc. Group retreats are generally — though not always — more affordable than fully bespoke one-on-one work. A reputable week-long ayahuasca retreat in Peru tends to run somewhere between $1,500 and $4,000, depending on accommodations, the number of ceremonies, and the lineage of the facilitators. Legal psilocybin retreats in the Netherlands, Jamaica, or Mexico typically land in a similar range. Ibogaine, because it requires medical supervision, runs higher — often $6,000 to $10,000 or more. Red flags to actually watch for, in any group container: The evidence base for group psychedelic therapy is still thinner than for individual models, partly because most clinical trials have been built around 1:1 dosing for regulatory reasons. But what exists is encouraging. Studies on group psilocybin for demoralisation in long-term AIDS survivors, group MDMA work for veterans, and various ayahuasca outcomes research have shown comparable benefits to individual protocols, sometimes with the added dimension of sustained community after the experience ends. The qualitative findings are perhaps more striking. Participants in group containers consistently report that the shared experience itself — the sense of journeying alongside others — was a core part of what made the work meaningful. Whether that translates into measurable clinical outcomes that beat individual therapy is still being studied. But for many people, the relational dimension isn't a side effect. It's the point. If you're someone who's been quietly considering a retreat — whether for depression that won't lift, an addiction that hasn't responded to anything else, trauma that lives in your body, or just a sense that something in your life needs to crack open — group plant medicine is worth taking seriously. It won't be right for everyone. But the loneliness most of us carry around like a second skeleton might not heal in isolation. For readers who want to take this further, a thoughtfully curated range of group ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here. Whatever container you choose, choose it carefully. Ask hard questions. Trust your gut about facilitators. And give yourself the integration time afterward — the medicine doesn't end when you leave the maloca.
Kambo Frog Medicine Explained: Benefits, Risks, and What a Ceremony Actually Feels Like
Picture this: it's dawn somewhere in the Acre region of Brazil, and a hunter is listening for a sound most of us would never recognize — the low, throaty call of a bright green tree frog that only sings at night. That frog is Phyllomedusa bicolor, the giant monkey frog, and the waxy secretion scraped gently from its back is what's now known across the world as kambo. Or sapo. Or, more dramatically, frog medicine. Kambo has been quietly bubbling up at the edges of the plant medicine scene for years. It's not psychedelic. It won't dissolve your ego or send you tunneling through fractal geometry. What it will do — and this is the part nobody quite prepares you for — is make your body do things you didn't think were possible in a thirty-minute window. And then, often, leave you feeling clearer than you've felt in months. If you're researching kambo because you've heard whispers about it at an ayahuasca retreat, or because a friend swears it pulled them out of a depressive fog, this guide is for you. Honest, specific, and not particularly interested in selling you anything. The medicine itself is a peptide-rich secretion produced by the giant monkey frog when it's stressed. Indigenous groups like the Matsés, Katukina, and Yawanawá have used it for generations — mostly to sharpen hunters before they head into the forest, but also for stamina, fertility, and what they describe as clearing panema, a kind of stagnant heavy energy that lingers around a person who's been unlucky, depressed, or spiritually off. The collection process is, by most accounts, surprisingly gentle. The frog is tied loosely by its limbs, the secretion is scraped onto a wooden stick, and then it's released back into the canopy. The dried venom keeps for over a year. It looks a bit like dried mustard. How does it actually get into you? Through small superficial burns on the skin — usually on the shoulder, leg, or chakra points if your practitioner leans that way. These tiny burns are called gates, and the kambo paste is dabbed directly onto them, bypassing the digestive system and going straight into the lymphatic flow. Within seconds, your body knows something has arrived. Let's not romanticize this. Kambo is intense. Not psychedelic-intense — physical-intense. Within thirty seconds of application, your heart starts pounding. Your face flushes. There's a strange internal pressure that sweeps through the body in waves, and somewhere around the two-minute mark, most people understand viscerally why this is sometimes called the warrior's medicine. Then comes the purge. Yes, you'll vomit — that's the point, and the bucket placed in front of you isn't decorative. Some people also have to run for the bathroom. The famous “frog face” can show up too: swollen lips, puffy eyes, a feeling that your throat has its own heartbeat. None of this is dangerous in a healthy person, though it's certainly memorable. The whole acute experience usually lasts 20 to 40 minutes. The first half is the heaviest. After that, the gates are cleaned, you drink water, you lie down, and your nervous system gradually puts itself back together. Most people report something quietly remarkable in the hours and days afterward — sharper focus, lifted mood, a feeling of having scrubbed something out of the body that words can't quite name. Others sleep for fourteen hours and feel slightly hungover. Both reactions are normal. Western interest in kambo started picking up because of the research of Italian pharmacologist Vittorio Erspamer, who spent decades studying the bioactive peptides in the frog's secretion. He famously described it as a chemical cocktail unmatched in the animal kingdom, with potential medical applications across a wide range of conditions. Subsequent research has identified peptides that affect the blood-brain barrier, modulate dopamine and serotonin, interact with opioid receptors, and influence the hypothalamic-pituitary-adrenal axis — the body's stress regulation system. That's the biochemistry. The lived experience is something else. People who work with kambo over time often report relief from conditions Western medicine has struggled with: I want to be careful here. None of this is a cure. None of it is FDA-approved. But there's enough anecdotal weight behind these reports, and enough early peptide research, that dismissing kambo entirely feels intellectually lazy. A 2012 University of Paris study found that one of its peptides, Dermaseptin B2, inhibited the growth of certain human tumor cell lines in vitro. That's a long way from clinical application, but it suggests there's something pharmacologically real happening here. No, kambo isn't a psychedelic. You won't trip. You won't see geometric beings. The peptides aren't serotonergic agonists in the way classic psychedelics are. That said, kambo is often paired with rapé (a tobacco-based snuff) or sananga (an eyedrop made from a Tabernaemontana root), and that combination can produce mild altered states — not psychedelic in the traditional sense, but definitely not ordinary consciousness either. Because kambo doesn't get you high in any legally recognizable way, it sits in a strange regulatory gray zone almost everywhere. In most of the United States, the UK, and Europe, it's not explicitly scheduled or banned — practitioners operate openly, often as part of broader plant-medicine retreat offerings. Brazil restricted its commercial sale back in 2004 at the request of the Katukina people, who were concerned about cultural exploitation. Australia placed restrictions on practitioners in several states after a death during a ceremony in 2019. The takeaway: the legal risk for participants is generally low in most Western countries, but laws shift and the situation deserves a fresh check before you book anything. Don't take a stranger's word for it. Here's where I get serious for a minute. Kambo is powerful, and powerful means there are people who shouldn't go near it. A reputable practitioner will screen you carefully. If they don't, walk away. Absolute contraindications usually include: The deaths associated with kambo — and they exist, though they're rare — have usually involved underlying cardiovascular conditions, excessive water consumption before the ceremony (which can cause hyponatremia), or practitioners who didn't screen properly. A 2017 study in Clinical and Experimental Hepatology also flagged the possibility of drug-induced liver injury, which is another reason proper preparation matters. This is not a medicine to take from a friend in their living room because they watched a YouTube video. Find an experienced practitioner — ideally one trained through the International Association of Kambo Practitioners or who has lineage with an indigenous teacher. If you've decided you want to try kambo, here's roughly what good preparation looks like. Most practitioners will give you a more detailed protocol, but the basics rarely vary much. Afterward, eat simply — broth, rice, fruit — and don't immediately throw yourself back into your inbox. The medicine keeps working for hours, sometimes days. Most experienced facilitators recommend no more than three ceremonies in close succession, and somewhere around 12 sessions per year as a reasonable upper limit. Individual sessions with reputable practitioners in the U.S. and Europe usually run between $100 and $250. Group ceremonies at retreat centers tend to be cheaper per person, sometimes bundled into broader plant-medicine programs that include ayahuasca, San Pedro, or psilocybin work. Multi-day retreats focused on kambo specifically — often three sessions over a long weekend — typically range from $400 to $1,000, depending on accommodation and location. Skip the cheapest option. With kambo, the practitioner's experience is the entire safety net. Pay for that. Honestly? Maybe. Maybe not. Kambo isn't a starting point for most people exploring plant medicine — it's usually something you arrive at after a few years of curiosity, often during an ayahuasca dieta or as part of a longer healing process. It's not gentle. It's not subtle. It doesn't deliver insight in the form of soft revelations. It's more like a hard reset for the body, and sometimes that reset is exactly what someone needs. If you're carrying something heavy — long-term depression, addiction patterns that have outlived every therapist, fatigue that no doctor has explained — kambo deserves a slot on the list of things worth investigating. So does ibogaine. So does ayahuasca. So does, frankly, a really good somatic therapist. The right tool depends on what you're actually carrying. For readers who want to take this further, a curated range of kambo and broader plant-medicine retreats can be browsed on our marketplace here. Take your time choosing. The frogs aren't going anywhere, and the right facilitator is worth waiting for.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
